Eureka Pharmaceuticals

Eureka Therapeutics is a clinical-stage biotechnology company focused on developing novel T-cell therapies for the treatment of solid tumors and hematologic malignancies. The company leverages its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform to engineer T-cells that can target intracellular cancer antigens, which are typically inaccessible to conventional CAR-T therapies. Its lead programs, including ECT204 and ET1402L1-ARTEMIS, target GPC3 and AFP-peptide/MHC complexes for the treatment of hepatocellular carcinoma. Eureka is headquartered in Emeryville, California, and maintains significant research and development operations aimed at overcoming the challenges of the solid tumor microenvironment.